 |
BeijingJune 2, 2026 /PRNewswire/ — XtalPi (2228.HK), a platform company driven by artificial intelligence (AI) and robotics for R&D innovation, today announced that its deeply incubated cutting-edge AI biology company, INFevo, has completed a tens of millions of yuan angel round of financing, co-participated by Shunwei Capital, Sequoia China, and Songhe Capital. INFevo focuses on building an AI-based “Virtual Cell System,” aiming to deeply decode the language of life, thereby precisely guiding innovative drug discovery and cell engineering design.
Currently, biomedical R&D generally faces the dilemma of extremely low clinical translation rates. Taking complex fields such as central nervous system diseases, immune diseases, and anti-aging as examples, the success rate of R&D has long hovered between 5% and 8%. The root cause is that the industry has always lacked a research system capable of representing and predicting the complex human system, and there is a huge species gap between animal models and humans, leading to the failure of a large number of candidate molecules in late-stage clinical trials. The key to solving this problem lies in moving from static structural understanding to dynamic system research. The scientific community generally believes that building high-fidelity virtual cells is a key technology to bridge the prediction gap from the laboratory to humans through system-level quantitative simulation.
To achieve this goal, INFevo adopts a dual-drive path of “full-stack AI foundational large models + high-throughput automated experiments.” By establishing digital models that can predict the evolution of cell states under genetic, chemical, and environmental perturbations, and forming a self-reinforcing “dry-wet closed loop,” it accelerates the process of moving virtual cells from a scientific concept to an industrial-grade efficient R&D tool.
Since its inception, INFevo has adhered to a global business perspective, directly targeting the core pain points of drug R&D, and has assembled a cross-disciplinary team with both strong underlying scientific capabilities and industrial delivery experience.
As a strategic project incubated internally by XtalPi, INFevo is highly synergistic with XtalPi in the drug innovation value chain. XtalPi possesses efficient design and screening capabilities at the “molecular level” and “structural level” in areas such as small molecules, large molecules, peptides, and nucleic acids, while INFevo provides AI models and translational predictions at the “cellular level” and “systems biology level.” The connection between the two will, for the first time, potentially bridge the long-standing gap between molecular optimization and translational prediction in the drug discovery chain, greatly deepening the moat of both parties’ capabilities.
Leveraging XtalPi’s industry experience as a leading listed technology company, its engineering delivery foundation, and global industrial resources, INFevo can quickly surpass the platform-building stage typical of startups. With the advantage of China’s rich scientific research and multi-dimensional clinical data resources, the company is expected to accelerate the complete closed loop from cutting-edge technological innovation to global commercial implementation. By building a virtual cell model based on an AI+Biology large model, it will collaborate with global pharmaceutical and bioengineering partners to jointly explore the “boundless evolution” of life sciences.
About INFevo
Beijing INFevo Technology Co., Ltd. (INFevo) is committed to building industry-leading AI virtual cell models, providing transformative biological research tools for global drug innovation. The company integrates the most advanced (SOTA) self-developed foundational large model OCOO in the biological field with automated and intelligent cell experimental platforms, creating a globally leading AI-era biomedical innovation research platform, thereby strongly supporting basic biology research breakthroughs. At the same time, by effectively connecting with clinical research, the company accelerates the translation and implementation of innovative achievements. Focusing on challenging research directions such as anti-aging, neurodegenerative diseases, autoimmune diseases, metabolic diseases, and tumors, INFevo is rapidly establishing a full-featured AI biology platform covering new mechanism and target discovery, virtual drug screening and evaluation, and clinical protocol optimization.
About XtalPi
XtalPi (“XtalPi Holdings Limited,” stock abbreviation: XtalPi Holdings, XTALPI, stock code: 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology. It is an innovative R&D platform based on quantum physics, empowered by artificial intelligence, and driven by robotics. The company combines quantum physics-based first-principles calculations, artificial intelligence, high-performance cloud computing, and scalable and standardized robotic automation to provide drug and materials science R&D solutions and services to global and domestic companies in the pharmaceutical and materials science industries (including agricultural technology, energy, new chemicals, and cosmetics).